scholarly journals RESPONSE: Re: Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents

2005 ◽  
Vol 97 (7) ◽  
pp. 541-542 ◽  
Author(s):  
F. Marini ◽  
M. Studeny ◽  
M. Andreeff
2004 ◽  
Vol 96 (21) ◽  
pp. 1593-1603 ◽  
Author(s):  
M. Studeny ◽  
F. C. Marini ◽  
J. L. Dembinski ◽  
C. Zompetta ◽  
M. Cabreira-Hansen ◽  
...  

2011 ◽  
Vol 26 (6) ◽  
pp. 767-773 ◽  
Author(s):  
Nedime Serakinci ◽  
Rikke Christensen ◽  
Umut Fahrioglu ◽  
Flemming Brandt Sorensen ◽  
Frederik Dagnæs-Hansen ◽  
...  

Biomedicines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 880
Author(s):  
Shamsul Bin Sulaiman ◽  
Shiplu Roy Chowdhury ◽  
Mohd Fauzi Bin Mh Busra ◽  
Rizal Bin Abdul Rani ◽  
Nor Hamdan Bin Mohamad Yahaya ◽  
...  

The tissue engineering approach in osteoarthritic cell therapy often requires the delivery of a substantially high cell number due to the low engraftment efficiency as a result of low affinity binding of implanted cells to the targeted tissue. A modification towards the cell membrane that provides specific epitope for antibody binding to a target tissue may be a plausible solution to increase engraftment. In this study, we intercalated palmitated protein G (PPG) with mesenchymal stem cells (MSCs) and antibody, and evaluated their effects on the properties of MSCs either in monolayer state or in a 3D culture state (gelatin microsphere, GM). Bone marrow MSCs were intercalated with PPG (PPG-MSCs), followed by coating with type II collagen antibody (PPG-MSC-Ab). The effect of PPG and antibody conjugation on the MSC proliferation and multilineage differentiation capabilities both in monolayer and GM cultures was evaluated. PPG did not affect MSC proliferation and differentiation either in monolayer or 3D culture. The PPG-MSCs were successfully conjugated with the type II collagen antibody. Both PPG-MSCs with and without antibody conjugation did not alter MSC proliferation, stemness, and the collagen, aggrecan, and sGAG expression profiles. Assessment of the osteochondral defect explant revealed that the PPG-MSC-Ab micromass was able to attach within 48 h onto the osteochondral surface. Antibody-conjugated MSCs in GM culture is a potential method for targeted delivery of MSCs in future therapy of cartilage defects and osteoarthritis.


2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Yuekui Zhao ◽  
Shanshan Tang ◽  
Jiamin Guo ◽  
Murad Alahdal ◽  
Shunxiu Cao ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Weiping Lin ◽  
Linfeng Huang ◽  
Ying Li ◽  
Bin Fang ◽  
Gang Li ◽  
...  

Stem cell-based therapies exhibit profound therapeutic potential for treating various human diseases, including cancer. Among the cell types that can be used for this purpose, mesenchymal stem cells (MSCs) are considered as promising source of stem cells in personalized cell-based therapies. The inherent tumor-tropic property of MSCs can be used to target cancer cells. Although the impacts of MSCs on tumor progression remain elusive, they have been genetically modified or engineered as targeted anticancer agents which could inhibit tumor growth by blocking different processes of tumor. In addition, there are close interactions between MSCs and cancer stem cells (CSCs). MSCs can regulate the growth of CSCs through paracrine mechanisms. This review aims to focus on the current knowledge about MSCs-based tumor therapies, the opportunities and challenges, as well as the prospective of its further clinical implications.


2014 ◽  
Author(s):  
Cuixia Yang ◽  
Danjuan Li ◽  
Bo Wang ◽  
Omaida C. Velazquez ◽  
Zhao-Jun Liu

Sign in / Sign up

Export Citation Format

Share Document